Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Immunotherapy ; 9(11): 889-897, 2017 09.
Article in English | MEDLINE | ID: mdl-28838282

ABSTRACT

AIM: A retrospective survival benefit analysis of APCEDEN®, APAC BIOTECH Pvt Ltd 69, Jacranda Marg, DLF PHASE II, Gurugram, Haryana, India, an autologous dendritic cell-based product for management of refractory solid malignancies, was performed in comparison with a control group. METHODS: Subjects (retrospective data) whose survival data, geographical region, age, gender, ECOG performance status and stage of disease that could be matched with the treatment group were considered for analysis. RESULTS: The analysis suggests a significant survival benefit of 199 days for the APCEDEN therapy treatment group when compared with the control group (356 vs 157 days). The event-free survival time of APCEDEN therapy was 439 days in patients who demonstrated an objective response at first evaluation as per immune-related response criteria. CONCLUSION: APCEDEN demonstrated highly convincing survival benefits when compared with the control group.


Subject(s)
Cancer Vaccines/therapeutic use , Dendritic Cells/transplantation , Immunotherapy, Adoptive/methods , Neoplasms/therapy , Palliative Care/methods , Cancer Vaccines/adverse effects , Cells, Cultured , Dendritic Cells/immunology , Female , Humans , Immunotherapy, Adoptive/adverse effects , Immunotherapy, Adoptive/mortality , Male , Neoplasms/immunology , Neoplasms/mortality , Neoplasms/pathology , Progression-Free Survival , Retrospective Studies , Time Factors , Treatment Outcome
2.
Cytotherapy ; 16(2): 234-44, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24438902

ABSTRACT

BACKGROUND AIMS: A phase II clinical trial of an autologous dendritic cell (DC) formulation for the management of refractory solid malignant tumors was conducted across six sites in India with an objective to study safety and efficacy. METHODS: A total of 51 patients with refractory cancer (either sex) with life expectancy ≥3 months, Eastern Cooperative Oncology Group score ≤2, available tumor tissue and adequate organ and bone marrow function were recruited. Monocytes obtained by leukapheresis, differentiated into DCs by cytokines and primed with autologous tumor lysate (fresh tissue biopsy or paraffin block). On the 8th day, mature DCs were analyzed for expression of CD40, CD80, CD83, CD86, DC205 and DC209. The treatment regime consisted of six doses (intravenous) over 14 weeks with 2 post-treatment follow-up visits, 6 weeks apart. Safety was assessed at all visits and responses were evaluated on days 58, 100 and 184 or at end of the study. RESULTS: A total of 38 patients were evaluated for safety and efficacy. One adverse event classified as possibly related was an episode of rigors or chills with mild pyrexia during one infusion. Objective response rate by Response Evaluation Criteria In Solid Tumors was 28.9% (11/38) and immune-related response criteria was 42.1% (16/38); 90% confidence interval for objective response rate was (17.2, 43.3) and (28.5, 56.7) by Response Evaluation Criteria In Solid Tumors and immune-related response criteria, respectively. The median time to treatment progression was >9 weeks. Median overall survival was 397 days. An increase in the expression of interferon-γ was not significant. CONCLUSIONS: Therapy was safe. The responses, time to treatment progression and survival are encouraging for patients with aggressive refractory disease.


Subject(s)
Cancer Vaccines , Carcinoma/therapy , Colonic Neoplasms/therapy , Dendritic Cells/transplantation , Head and Neck Neoplasms/therapy , Immunotherapy/methods , Ovarian Neoplasms/therapy , Adult , Aged , Antigens, CD/metabolism , Antigens, Neoplasm/immunology , Antigens, Neoplasm/metabolism , Carcinoma/immunology , Carcinoma/mortality , Cell Differentiation , Cell Extracts/immunology , Cells, Cultured , Colonic Neoplasms/immunology , Colonic Neoplasms/mortality , Cytokines/immunology , Dendritic Cells/immunology , Drug Resistance, Neoplasm , Female , Follow-Up Studies , Head and Neck Neoplasms/immunology , Head and Neck Neoplasms/mortality , Humans , India , Male , Middle Aged , Ovarian Neoplasms/immunology , Ovarian Neoplasms/mortality , Recurrence , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...